BLFS: financial statements from SEC — TradeAlmanac

BLFS

BioLife Solutions, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	96m	75m
Cost of revenue	34m	25m
Gross profit	62m	50m
Research and development	8m	5m
Selling, general and administrative	46m	41m
Operating expenses	79m	55m
Operating income	−17m	−4m
Pre-tax income	−12m	−9m
Income tax	49,000	−38,000
Net income	−5m	−20m
Earnings per share	−0.09	−0.44
Earnings per share, diluted	−0.10	−0.44
Weighted average shares	48m	46m
Weighted average shares, diluted	49m	46m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	23m	33m	29m	32m	67m	92m	24m	22m
Receivables	13m	8m	11m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	20m	8m
Depreciation and amortisation	2m	5m
Share-based compensation	23m	31m
Capital expenditure	9m	3m
Investing cash flow	−72m	58m
Financing cash flow	−11m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)